新闻BenzingaVivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M Benzinga 2026.10.15 12:48 (GMT+0) 在Benzinga上打开 其他新闻 特朗普：数据中心企业应向所在社区支付“红利” 马斯克公开表态或致SpaceX与特斯拉合并谈判延迟数周 马斯克警告民主党：若调查自己及旗下企业，将予以反击 CoinDCX疑似被盗约1600万 USDT，资金已拆分转入多家交易所 PHP严重漏洞曝光后攻击激增，Cloudflare监测到数百万次尝试 argenx第三季度每股收益7.80美元，低于预期的7.83美元；销售额17.51亿美元，高于预期的16.64亿美元
